GSK press releases
Follow
Blenrep (belantamab mafodotin) combinations receive positive CHMP opinion in relapsed/refractory multiple myeloma
Positive opinion supported by superior efficacy shown in two head-to-head phase III trials, including overall survival in DREAMM-7.
